相关实验视频

Updated: May 23, 2025

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

罗西格利塔在通过PPAR-γ通路调节痕形成方面的治疗潜力

Qing-Qing Fang¹, Yang-Jun Gu², Yong Wang¹

¹Department of Plastic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.

European journal of pharmacology

|March 7, 2025

概括

罗西格利塔是一种PPAR-γ激动剂,通过调节葡萄糖和脂质代谢,有效地减少痕形成. 这项研究突出了其作为痕治疗新疗法的潜力.

科学领域:

生物化学生物化学
皮肤病学皮肤病学
药理学药理学是指药理学的学科.

背景情况:

伤的预防和治疗仍然是一个重要的医疗挑战.
需要安全,有效和负担得起的痕疗法.
代谢途径,特别是葡萄糖和脂质代谢,都与痕的发展有关.

研究的目的:

为了研究酶增殖器激活受体-γ (PPAR-γ) 在痕形成中的作用.
评估PPAR-γ激动剂罗西格利塔在缓解痕形成方面的疗效.
阐明罗西格利塔对痕组织作用的潜在机制.

主要方法:

使用非向代谢和RNA测序来分析痕组织.
在老鼠身上建立了痕模型,并给出了罗西格利塔.
在体外研究中使用转化生长因子β1 (TGF-β1) 刺激纤维细胞 (NIH 3T3和3T3 L1).

主要成果:

罗西格利塔对PPAR-γ的激活显著阻碍了纤维化,并在体内和体外减少了痕形成.
罗西格利塔降低了炎症因素,甘油三,乳酸,糖原和乳酸脱酶水平的调节.
罗西格利塔增加了腺三酸盐 (ATP) 生产,自由脂肪酸水平,以及关键代谢酶的活性.

结论:

罗西格利塔显示出作为减少痕的治疗剂的显著潜力.
通过PPAR-γ激活调节葡萄糖和脂质代谢是减轻痕的关键机制.
这些发现为使用罗西格利塔来缓解纤维化和减少痕形成提供了机制基础.

关键词:

葡萄糖脂类的新陈代谢炎症炎症是一种炎症.炎症性细胞因子是炎症性细胞因子.在PPAR-γ中使用PPAR.罗西格利塔 (Rosiglitazone) 是一种有毒的药物.痕的形成痕的形成

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Clinical Applications of Epidermal Stem Cells

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...